Fusion Antibodies collab using AI to generate humanized antibodies

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/jirsak)
(Image: Getty/jirsak)

Related tags: Collaboration, Antibody, Clinical trial, CRO, analytics, Artificial intelligence, Manufacturing, Clinical trial management

Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.

The collaboration between Fusion Antibodies, a contract research organization (CRO), and Analytics Engines will incorporate machine learning (ML) and artificial intelligence (AI) into Fusion Antibodies’ CDRx humanization platform.

CDRx, according to Fusion, can perform multiple virtual experiments through AI and ML with panels of selected antibodies to discover properties needed to meet desired functionality and developability requirements.

The partnership aims to increase the platform’s AI and ML capabilities to further its abilities. Through this, Fusion may reach its long-term goal of reducing development costs and accelerating clinical timelines, it said.

Paul Kerr, CEO of Fusion Antibodies told us that the relationship, “will aid the development and the high throughput humanization of large-scale B-Cell repertoires to give more efficacious precision molecules rapidly.”

Currently, the CDRx platform uses the traditional clinical data repository (CDR) grafting technique while implementing in silico​ grafting parental CDR’s into mature human antibody frameworks. It screens a database of roughly 100,000 use antibody sequences and can generate full-length humanized antibodies that can be refined to reach a level that further resembles human antibodies. 

Through the collaboration, Analytics Engines will be able to assist in the creation of ML models to improve Fusion’s antibody humanization process, said, Aislinn Rice, CEO of Analytics Engines in a press release.

“This will allow clients to create a large panel of humanized antibodies directly from multiple species allowing drug candidates to be screened quickly reducing time to clinical development,”​ said Kerr.

Kerr also stated that the partnership with Analytics Engines will bolster Fusion’s product quality and manufacturability.

Fusion received a €213,000 ($283,231) grant​ from Invest NI, a Northern Ireland development agency. Fusion said it would use the grant to develop its business and grow  its workforce. 

This collaboration comes after Fusion expressed its interest in differentiating its services into ML and AI​ as a way of competing with so called ‘pop-up consultants’ that had entered the field of humanization.

CROs have been incorporating AI more recently. Saama launched its first set of AI capabilities​ to support clinical trial planning and conduct. Its technology uses a “deep learning intelligent assistant” to use natural language processing and natural language understanding.

In drug discovery, Insilico Medicine and Juvenescence​ signed a multi-year drug development agreement to use AI in an aim to advance compounds. 

Related news

Show more

Related products

show more

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more